FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Undertreated Volume and Tumor Morphology as Predictors of Outcome Following Thermal Ablation of 3-7-cm Hepatocellular Carcinoma. PMID 40609677 · J Vasc Interv Radiol · 2025-Oct The study is an original analysis from a randomized trial but does not present a drug-containing intervention as the primary focus of this report (ThermoDox is mentioned as part of the prior trial, but this analysis is a retrospective sub-study on imaging predictors). More critically, the primary endpoints are predictors of local recurrence and survival via univariate/multivariate analysis (p-values), not a formal time-to-event efficacy report with Kaplan-Meier curves, hazard ratios, or survival probabilities as the primary outcome. The 'survival' outcome is mentioned as a correlation, not as a reported time-to-event endpoint with event rates or curves. Therefore, it does not meet the time-to-event efficacy requirement for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ensifentrine: A Novel Option for Maintenance of Chronic Obstructive Pulmonary Disease. PMID 40575474 · J Pharm Technol · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. PMID 40555305 · Ann Allergy Asthma Immunol · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Double-Blind Crossover Study of Change in Post-Dose Lung Function with Hydrofluoroolefin-1234ze, a Next-Generation Propellant for Metered Dose Inhalers, in Participants with Asthma. PMID 40551410 · J Aerosol Med Pulm Drug Deliv · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Renal resistance trajectories during hypothermic machine perfusion in kidneys donated after circulatory death: Associations with donor characteristics and posttransplant outcomes-An analysis of COMPARE trial data. PMID 40550469 · Am J Transplant · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Single-Center, Randomized Controlled Trial. PMID 40545499 · Chin J Integr Med · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial. PMID 40544121 · Eur Urol · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial. PMID 40543844 · Ann Oncol · 2025-Oct 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study. PMID 40543832 · Fertil Steril · 2025-Oct This is a randomized, double-blind, placebo-controlled Phase 3 trial of a drug (linzagolix) for uterine fibroids (non-cancerous, benign neoplasm). The primary efficacy endpoint is a categorical response (reduction in heavy menstrual bleeding to <80 mL and >50% reduction), not a time-to-event outcome such as OS, PFS, DFS, RFS, TTP, or survival analyzed via Kaplan-Meier/HR. Therefore, it does not meet the oncology or time-to-event criteria for inclusion in the cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial. PMID 40541863 · Ann Oncol · 2025-Oct The report is a secondary analysis of health-related quality of life from a Phase III randomized trial. It does not present primary or key secondary time-to-event efficacy endpoints (e.g., OS, PFS) with Kaplan-Meier or HR. Therefore, it is excluded. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Extended-release buprenorphine treatment for opioid use disorder: A mixed-methods study of response and experience. PMID 40538333 · Addiction · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: Results from Cancer and Leukemia Group B 140503 (Alliance). PMID 40532782 · J Thorac Cardiovasc Surg · 2025-Oct The study is a randomized trial in oncology with time-to-event efficacy endpoints (DFS, RFS) and original results, but it does not involve a drug-containing intervention. The intervention is surgical (lobar vs. sublobar resection) and the analysis examines the extent of lymph node dissection. Therefore, it fails the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial. PMID 40523501 · J Thromb Haemost · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial. PMID 40505670 · Lancet Infect Dis · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials. PMID 40501427 · Leuk Lymphoma · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Construction and application of a nomogram model for predicting postoperative cerebral edema in meningiomas based on radiomics and clinical features. PMID 40474660 · Acta Radiol · 2025-Oct This is an oncology randomized trial in humans with original results, but it is excluded because the intervention is a non-drug predictive model (radiomics and clinical features) for guiding diagnosis/treatment, and it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) using Kaplan-Meier or HR. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma. PMID 40438087 · Liver Cancer · 2025-Oct The record describes a matching-adjusted indirect comparison (MAIC) of two separate trials. While it analyzes time-to-event data (OS, PFS) and involves drug interventions, it is not the primary report of a randomized trial. The required criteria of an 'original formal-result report of a randomized trial' is not met. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer. PMID 40434336 · J Perianesth Nurs · 2025-Oct The study is a randomized controlled trial in oncology (lung cancer surgery) with a drug intervention (ropivacaine and esketamine), but it is a perioperative analgesia study, not a definitive therapeutic trial evaluating a cancer-specific time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study. PMID 40412421 · Lancet Infect Dis · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia. PMID 40407269 · Leuk Lymphoma · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease. PMID 40401357 · J Clin Pharmacol · 2025-Oct The study is a pharmacokinetic and exposure-response analysis from a Phase III trial in Crohn's disease (inflammatory bowel disease), which is a non-oncology condition. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS) for a human malignant neoplasm. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. PMID 40393861 · Eur Urol · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Underdiagnosis of positive resection margins and synchronous peritoneal metastases in locally advanced colon cancer: histopathological reassessment of primary resection in the COLOPEC trial. PMID 40374989 · Virchows Arch · 2025-Oct The report is a pathological analysis of the COLOPEC trial (which is a randomized trial with a drug intervention and time-to-event endpoints), but it is not the primary/definitive efficacy report of the trial itself. Furthermore, the explicit trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the provided metadata, which is a required criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. PMID 40360369 · Clin Lymphoma Myeloma Leuk · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial. PMID 40289847 · Arthritis Rheumatol · 2025-Oct The study is a randomized controlled trial of a tumor necrosis factor inhibitor in rheumatoid arthritis, which is not an oncology/malignant neoplasm indication. Therefore, it does not meet the primary oncology eligibility criterion for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An Online Treatment Decision Aid for Men with Low-risk Prostate Cancer Eligible for Active Surveillance and Their Partners Increases the Uptake of Active Surveillance: The Navigate Randomised Controlled Trial. PMID 40222891 · Eur Urol Oncol · 2025-Oct The study is a randomized controlled trial in low-risk prostate cancer, but it evaluates a decision aid (non-drug intervention) and its primary endpoint is uptake of active surveillance (a categorical treatment choice), not a time-to-event efficacy endpoint like OS, PFS, or DFS. No Kaplan-Meier or hazard ratio results are reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Are cefiderocol or sulbactam/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review. PMID 40192957 · Infection · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials. PMID 40147791 · J Hepatol · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia. PMID 40145363 · Ann Pharmacother · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Complex, low-intensity, individualised naturalistic developmental behavioural intervention in toddlers and pre-schoolers with autism spectrum disorder: The multicentre, observer-blind, parallel-group randomised-controlled A-FFIP trial. PMID 40135359 · J Child Psychol Psychiatry · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fractional flow reserve or OCT to guide management of complex and noncomplex angiographically intermediate coronary stenosis. PMID 40107654 · Rev Esp Cardiol (Engl Ed) · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effectiveness comparison between ceftazidime-avibactam and carbapenem-based regimens in nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections. PMID 40059019 · J Microbiol Immunol Infect · 2025-Oct The study is a retrospective, observational, single-center study in infectious diseases (nosocomial bacteremia), not an oncology randomized controlled trial. It does not meet the required oncology, randomized, or Phase III criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Undisclosed Conflicts of Interest in Japanese Cancer Clinical Trials: A Cross-Sectional Study of Author-Pharmaceutical Industry Financial Relationships. PMID 40030121 · JCO Oncol Pract · 2025-Oct The record is a cross-sectional study analyzing conflicts of interest in Japanese cancer clinical trials. While it references Phase III randomized trials, the study itself is not an original report of a trial's efficacy results. It lacks any time-to-event efficacy endpoint and does not present drug intervention outcomes from a specific trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Endoscopic suturing to prevent migration of esophageal fully covered self-expandable metal stents: a randomized controlled trial (with video). PMID 40024292 · Gastrointest Endosc · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Physical recovery after local resection of nonpedunculated rectal adenomas and T1 carcinomas: endoscopic submucosal dissection versus transanal minimally invasive surgery. PMID 39956469 · Gastrointest Endosc · 2025-Oct The study is excluded because it is not a drug intervention trial and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier analysis or hazard ratio. The primary endpoint is mean time to recovery, a functional outcome, not a survival endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment. PMID 39909280 · Clin Gastroenterol Hepatol · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized comparison of precut papillotomy versus an endoscopic ultrasound-guided rendezvous procedure for difficult biliary access in malignant distal biliary obstruction. PMID 39799946 · Endoscopy · 2025-Oct The study is a randomized controlled trial in an oncology context, but it compares two procedural techniques (endoscopic interventions) and does not involve a drug-containing intervention. The primary and secondary outcomes are technical success, adverse events, procedure duration, and length of stay, which are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. PMID 39317633 · Eur Urol · 2025-Oct The record describes a final analysis of patient-reported outcomes (quality of life, pain deterioration, tolerability) from a Phase III randomized trial. While the trial itself meets oncology, human, randomized, phase, and drug-intervention criteria, the reported results are not for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and do not feature Kaplan-Meier or HR for efficacy. It is a secondary analysis focusing on PROs, not efficacy. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial. PMID 38913220 · Cardiovasc Drugs Ther · 2025-Oct 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effect of lobar versus sublobar video-assisted thoracoscopic surgery lung resection on patient quality of life. PMID 41376921 · J Thorac Dis · 2025-Nov-30 Study is a non-randomized, retrospective analysis of surgical procedures (lobectomy vs. sublobar resection) for lung cancer with a primary quality-of-life endpoint, not a randomized drug trial with a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Role of fallopian tube and cervical canal occlusion in preventing intra-operative tumour spillage in early endometrial cancer- a pilot study. PMID 41318519 · World J Surg Oncol · 2025-Nov-29 The study is a pilot randomized trial of a surgical technique (cervical/tubal occlusion) to prevent tumor spillage in endometrial cancer, without a drug intervention, and does not report a time-to-event efficacy endpoint. It is not a Phase III or definitive randomized trial of a drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials. PMID 41318485 · Arthritis Res Ther · 2025-Nov-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of lidocaine versus sufentanil in patient-controlled intravenous analgesia after laparoscopic colorectal cancer surgery: a prospective, randomized, double-blind clinical trial. PMID 41318377 · BMC Anesthesiol · 2025-Nov-29 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Is there a difference in the postoperative quality of recovery and analgesia between erector spinae and serratus anterior plane blocks following modified radical mastectomy: a randomized controlled study. PMID 41315952 · BMC Anesthesiol · 2025-Nov-29 The study is a randomized controlled trial in oncology patients but compares two regional anesthesia techniques (erector spinae plane block vs. serratus anterior plane block) for postoperative analgesia and recovery quality. It is not a Phase III/IIIb or Phase II/III trial of a systemic drug intervention. The primary endpoint is a patient-reported quality of recovery score (QoR-40), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR is reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer. PMID 41316390 · Breast Cancer Res · 2025-Nov-28 The record describes a non-randomized, single-arm, Phase 1b/2 trial. The primary efficacy endpoint is pathological complete response (pCR), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for a randomized trial with a time-to-event primary/key secondary endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts. PMID 41316297 · Respir Res · 2025-Nov-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer. PMID 41316032 · BMC Cancer · 2025-Nov-28 The record is a Phase 4 observational, retrospective, non-randomized study. It does not meet the inclusion criteria for an original formal result of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors. PMID 41315323 · Sci Rep · 2025-Nov-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial. PMID 41315271 · Nat Commun · 2025-Nov-28 The report is a randomized, oncology trial with drug intervention and time-to-event efficacy (EFS), but it is explicitly described as a 'pilot trial' and lacks evidence of being Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis. PMID 41314984 · J Immunother Cancer · 2025-Nov-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |